EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients

Trial Details

NCT ID
NCT05883852
Phase
PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Docetaxel
  • carboplatin
  • Trastuzumab
  • Pertuzumab
  • Epirubicin
  • cyclophosphamide
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Women aged 18-70；
  • 0-1 for ECOG；
  • Unilateral invasive carcinoma confirmed by histology (regardless of pathological type)；
  • No gross or microscopic tumor remains after surgical resection；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →